Long-term outcomes of the use of a polytetrafluoroethylene-valved conduit for right ventricular outflow tract reconstruction in adult Ross patients

BACKGROUND: To reconstruct the right ventricular outflow tract (RVOT) during the Ross procedure, various types of conduits are used. However, their application is often limited due to donor availability. A polytetrafluoroethylene (PTFE) valved conduit can be considered a viable alternative. METHODS: This study summarizes 17 years of experience with RVOT reconstruction via polytetrafluoroethylene (PTFE)-valved conduits in adult patients who underwent the Ross procedure. To collect data, an extensive search of our clinic’s medical database was conducted. Follow-up data were collected either via phone calls or during in-person visits. RESULTS: Between 2007 and 2018, 20 adult patients (> 18 years old) who underwent RVOT reconstruction with PTFE valved conduits were retrospectively analysed. The mean patient age was 39.8 ± 14.3 years, and the mean follow-up period was 9.9 ± 3.5 years. Echocardiography was used to assess conduit function during follow-up. There was one early death and one late death. The mean conduit size was 25.3 ± 1.5 mm, and the mean peak RVOT gradient was 23.3 ± 11.7 mmHg. Mild or less regurgitation was observed in 7 patients (35%), moderate - in 2 patients (10%), with no cases of severe regurgitation observed. Freedom from conduit dysfunction at the latest follow-up was 90%. Conduit replacement was successfully performed in one patient. CONCLUSIONS: For RVOT reconstruction in adult patients undergoing the Ross procedure, a PTFE valved conduit is a feasible alternative without compromising surgical outcomes. TRIAL REGISTRATION: Retrospectively registered.